Probe dependence in the allosteric modulation of a G protein-coupled receptor: Implications for detection and validation of allosteric ligand effects

Molecular Pharmacology

Volumn 81, Issue 1, 2012, Pages 41-52

  Valant, Celine ^a   Felder, Christian C ^b   Sexton, Patrick M ^a   Christopoulos, Arthur ^a  

^a MONASH UNIVERSITY   (Australia)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 5 CHLORO 6 METHOXY 4 METHYLTHIENO[2,3 B]PYRIDINE 2 CARBOXYLIC ACID CYCLOPROPYLAMIDE; [4 [(3 CHLOROPHENYL)CARBAMOYLOXY] 2 BUTYNYL]TRIMETHYLAMMONIUM; ACETYLCHOLINE; G PROTEIN COUPLED RECEPTOR; GUANOSINE 5' O (3 THIO)TRIPHOSPHATE; LY 2033298; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUSCARINIC M2 RECEPTOR; MUSCARINIC M2 RECEPTOR AGONIST; OXOTREMORINE; OXOTREMORINE M; PHOSPHATE; PILOCARPINE; TETRAMETHYLAMMONIUM; UNCLASSIFIED DRUG; XANOMELINE;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG EFFECT; DRUG PROTEIN BINDING; LIGAND BINDING; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; LIGANDS; NICOTINIC ACIDS; PROTEIN BINDING; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M4; RECEPTORS, G-PROTEIN-COUPLED; REPRODUCIBILITY OF RESULTS; THIOPHENES;

EID: 84455173446     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.074872     Document Type: Article

References (39)

1. Aurelio L, Valant C, Flynn BL, Sexton PM, Christopoulos A, and Scammells PJ (2009) Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. J Med Chem 52:4543-4547.
2. Avlani VA, Gregory KJ, Morton CJ, Parker MW, Sexton PM, and Christopoulos A (2007) Critical role for the second extracellular loop in the binding of both orthosteric and allosteric G protein-coupled receptor ligands. J Biol Chem 282:25677-25686. (Pubitemid 47372845)
3. Birdsall NJ and Lazareno S (2005) Allosterism at muscarinic receptors: ligands and mechanisms. Mini Rev Med Chem 5:523-543. (Pubitemid 40754167)
4. Caulfield MP (1993) Muscarinic receptors-characterization, coupling and function. Pharmacol Ther 58:319-379.
5. Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christopoulos A, Lazareno S, Birdsall NJ, Bymaster FP, et al. (2008) Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci USA 105:10978-10983.
6. Christopoulos A (1998) Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. Trends Pharmacol Sci 19:351-357.
7. Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1:198-210.
8. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374. (Pubitemid 34575719)
9. Christopoulos A, Sorman JL, Mitchelson F, and El-Fakahany EE (1999) Characterization of the subtype selectivity of the allosteric modulator heptane-1,7-bis- (dimethyl-3′-phthalimidopropyl) ammonium bromide (C7/3-phth) at cloned muscarinic acetylcholine receptors. Biochem Pharmacol 57:171-179. (Pubitemid 29056178)
10. Conn PJ, Christopoulos A, and Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8:41-54.
11. Eglen RM, Choppin A, and Watson N (2001) Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol Sci 22:409-414. (Pubitemid 32718632)
12. Gregory KJ, Hall NE, Tobin AB, Sexton PM, and Christopoulos A (2010) Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J Biol Chem 285:7459-7474.
13. Gregory KJ, Sexton PM, and Christopoulos A (2007) Allosteric modulation of muscarinic acetylcholine receptors. Curr Neuropharmacol 5:157-167. (Pubitemid 351863857)
14. Hall DA (2000) Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol Pharmacol 58:1412-1423.
15. Heitz F, Holzwarth JA, Gies JP, Pruss RM, Trumpp-Kallmeyer S, Hibert MF, and Guenet C (1999) Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site. Eur J Pharmacol 380:183-195. (Pubitemid 29469529)
16. Kenakin T (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4:919-927.
17. Keov P, Sexton PM, and Christopoulos A (2011) Allosteric modulation of G proteincoupled receptors: a pharmacological perspective. Neuropharmacology 60:24-35.
18. Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL, Miller LJ, Summers RJ, Christopoulos A, and Sexton PM (2010) Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol 78:456-465.
19. Kostenis E and Mohr K (1996) Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. Trends Pharmacol Sci 17:280-283. (Pubitemid 26261891)
20. Lanzafame AA, Christopoulos A, and Mitchelson F (2003) Cellular signaling mechanisms for muscarinic acetylcholine receptors. Receptors Channels 9:241-260. (Pubitemid 37069446)
21. Lazareno S and Birdsall NJ (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48:362-378.
22. Lazareno S and Birdsall N (1996) Quantitation of allosteric interactions. Trends Pharmacol Sci 17:443-444. (Pubitemid 27028475)
23. Leach K, Davey AE, Felder CC, Sexton PM, and Christopoulos A (2011) The role of transmembrane domain 3 in the actions of orthosteric, allosteric, and atypical agonists of the M4 muscarinic acetylcholine receptor. Mol Pharmacol 79:855-865.
24. Leach K, Loiacono RE, Felder CC, McKinzie DL, Mogg A, Shaw DB, Sexton PM, and Christopoulos A (2010) Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 35:855-869.
25. Leach K, Sexton PM, and Christopoulos A (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 28:382-389. (Pubitemid 47087967)
26. Liapakis G, Chan WC, Papadokostaki M, and Javitch JA (2004) Synergistic contributions of the functional groups of epinephrine to its affinity and efficacy at the β2adrenergic receptor. Mol Pharmacol 65:1181-1190. (Pubitemid 38543488)
27. Matsui H, Lazareno S, and Birdsall NJ (1995) Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. Mol Pharmacol 47:88-98.
28. May LT, Avlani VA, Langmead CJ, Herdon HJ, Wood MD, Sexton PM, and Christopoulos A (2007a) Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. Mol Pharmacol 72:463-476. (Pubitemid 47124126)
29. May LT, Leach K, Sexton PM, and Christopoulos A (2007b) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51. (Pubitemid 46277033)
30. Nawaratne V, Leach K, Felder CC, Sexton PM, and Christopoulos A (2010)Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. J Biol Chem 285:19012-19021.
31. Nawaratne V, Leach K, Suratman N, Loiacono RE, Felder CC, Armbruster BN, Roth BL, Sexton PM, and Christopoulos A (2008) New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Mol Pharmacol 74:1119-1131.
32. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A, McIntosh L, Goodwin G, Walker G, et al. (2005) Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68:1484-1495. (Pubitemid 41540004)
33. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, and Felder CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165:1033-1039.
34. Spalding TA, Ma JN, Ott TR, Friberg M, Bajpai A, Bradley SR, Davis RE, Brann MR, and Burstein ES (2006) Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation. Mol Pharmacol 70:1974-1983. (Pubitemid 44771913)
35. Stewart GD, Valant C, Dowell SJ, Mijaljica D, Devenish RJ, Scammells PJ, Sexton PM, and Christopoulos A (2009) Determination of adenosine A1 receptor agonist and antagonist pharmacology using Saccharomyces cerevisiae: implications for ligand screening and functional selectivity. J Pharmacol Exp Ther 331:277-286.
36. Suratman S, Leach K, Sexton P, Felder C, Loiacono R, and Christopoulos A (2011) Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. Br J Pharmacol 162:1659-1670.
37. Valant C, Gregory KJ, Hall NE, Scammells PJ, Lew MJ, Sexton PM, and Christopoulos A (2008) A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J Biol Chem 283:29312-29321.
38. Wess J (2005) Allosteric binding sites on muscarinic acetylcholine receptors. Mol Pharmacol 68:1506-1509.
39. Wess J, Eglen RM, and Gautam D (2007) Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 6:721-733. (Pubitemid 47342315)